567 related articles for article (PubMed ID: 10202050)
1. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
[TBL] [Abstract][Full Text] [Related]
2. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.
Herremans MM; van Loon AM; Reimerink JH; Rümke HC; van der Avoort HG; Kimman TG; Koopmans MP
Clin Diagn Lab Immunol; 1997 Sep; 4(5):499-503. PubMed ID: 9302194
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population.
Herremans T; Kimman TG; Conyn-Van Spaendonck MA; Buisman A; de Melker H; Abbink F; Bijkerk P; Koopmans MP
Clin Infect Dis; 2002 Apr; 34(8):1067-75. PubMed ID: 11914995
[TBL] [Abstract][Full Text] [Related]
5. Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.
Dey A; Molodecky NA; Verma H; Sharma P; Yang JS; Saletti G; Ahmad M; Bahl SK; Wierzba TF; Nandy RK; Deshpande JM; Sutter RW; Czerkinsky C
PLoS One; 2016; 11(1):e0146010. PubMed ID: 26730586
[TBL] [Abstract][Full Text] [Related]
6. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
[TBL] [Abstract][Full Text] [Related]
7. Mucosal responses to parenteral and mucosal vaccines.
Kaul D; Ogra PL
Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424
[TBL] [Abstract][Full Text] [Related]
8. Mucosal and systemic immunity against poliovirus in mice transgenic for the poliovirus receptor: the poliovirus receptor is necessary for a virus-specific mucosal IgA response.
Buisman AM; Sonsma JA; Kimman TG; Koopmans MP
J Infect Dis; 2000 Mar; 181(3):815-23. PubMed ID: 10720499
[TBL] [Abstract][Full Text] [Related]
9. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
11. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
Ivanov AP; Dragunsky EM; Chumakov KM
J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
[TBL] [Abstract][Full Text] [Related]
12. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion.
Valtanen S; Roivainen M; Piirainen L; Stenvik M; Hovi T
J Infect Dis; 2000 Jul; 182(1):1-5. PubMed ID: 10882574
[TBL] [Abstract][Full Text] [Related]
13. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
[TBL] [Abstract][Full Text] [Related]
14. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
[TBL] [Abstract][Full Text] [Related]
16. Trial of a supplemental dose of four poliovirus vaccines.
Sutter RW; Suleiman AJ; Malankar P; Al-Khusaiby S; Mehta F; Clements GB; Pallansch MA; Robertson SE
N Engl J Med; 2000 Sep; 343(11):767-73. PubMed ID: 10984564
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of inactivated poliomyelitis vaccine for primary vaccination].
Li CG; Ying ZF; Wang JF; Fang HH; Li YP; Li RC; Bonnet MC; Zhang YP
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jun; 43(6):501-3. PubMed ID: 19950717
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
[TBL] [Abstract][Full Text] [Related]
20. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
